1-(3,5-Dimethylpyridin-2-yl)piperazine → [2-Bromo-4-(1,1-dioxo-1lambda6-isothiazolidin-2-ylmethyl)phenyl][4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone
反応式
[Br:1][C:2]1[CH:11]=[C:10]([CH2:12][N:13]2[CH2:17][CH2:16][CH2:15][S:14]2(=[O:19])=[O:18])[CH:9]=[CH:8][C:3]=1[C:4]([O:6]C)=O.[CH3:20][C:21]1[C:22]([N:28]2[CH2:33][CH2:32][NH:31][CH2:30][CH2:29]2)=[N:23][CH:24]=[C:25]([CH3:27])[CH:26]=1>>[Br:1][C:2]1[CH:11]=[C:10]([CH2:12][N:13]2[CH2:17][CH2:16][CH2:15][S:14]2(=[O:19])=[O:18])[CH:9]=[CH:8][C:3]=1[C:4]([N:31]1[CH2:32][CH2:33][N:28]([C:22]2[C:21]([CH3:20])=[CH:26][C:25]([CH3:27])=[CH:24][N:23]=2)[CH2:29][CH2:30]1)=[O:6]参加物
3
実験手順
Using methyl 2-bromo-4-(1,1-dioxo-1λ6-isothiazolidin-2-ylmethyl)benzoate (312 mg) described in Preparation Example 177 and 1-(3,5-dimethylpyridin-2-yl)piperazine (171 mg) described in Preparation Example 79 and by the reaction and treatment in the same manner as in Example 109, the title compound (384 mg) was obtained.
後処理
- customdescribed in Preparation Example 79 and by the reaction and treatment in the same manner as in Example 109